Ruf Melanie, Moch Holger, Schraml Peter
Institute of Surgical Pathology, University Hospital Zurich, Switzerland.
Int J Cancer. 2016 Jul 15;139(2):396-403. doi: 10.1002/ijc.30077. Epub 2016 Mar 25.
In our study, we demonstrate that ccRCC cell lines with impaired function of pVHL to degrade HIFα express elevated levels of PD-L1. In vitro analysis provided evidence that both reconstitution of pVHL and silencing of HIF2α, but not of HIF1α, lead to reduced PD-L1 expression. The strong correlation of expression between the HIF2α-specific HIF target Glut1 and PD-L1 confirmed this finding in ccRCC cell lines and tissue. Soluble PD-L1 levels remained constant in the sera of ccRCC patients regardless of the PD-L1 expression status in their tumors. In conclusion, our data suggest PD-L1 as HIF2α target, which is upregulated in pVHL deficient ccRCC. The combination of PD-L1 targeting drugs with HIF inhibiting agents may be an additional option for the treatment of ccRCC.
在我们的研究中,我们证明了pVHL降解HIFα功能受损的ccRCC细胞系表达升高水平的PD-L1。体外分析表明,pVHL的重建和HIF2α的沉默(而非HIF1α的沉默)均导致PD-L1表达降低。HIF2α特异性HIF靶标Glut1与PD-L1之间的表达强相关性在ccRCC细胞系和组织中证实了这一发现。无论ccRCC患者肿瘤中的PD-L1表达状态如何,其血清中可溶性PD-L1水平保持恒定。总之,我们的数据表明PD-L1是HIF2α的靶标,在pVHL缺陷的ccRCC中上调。将靶向PD-L1的药物与HIF抑制剂联合使用可能是治疗ccRCC的另一种选择。